Analysis of clinical experience with angiotensin II: A meta-analysis and 4 AI.

OBJECTIVE Angiotensin II (ATII) was approved for distributive shock in Spain (2023). The objective is to assess the experience with ATII by comparing a meta-analysis (MTA) and 4 Artificial Intelligence (AI) tools. DESIGN A search was conducted in Pubmed®, Central®, Embase®, and Scopus®. Randomized clinical trials, non-randomized trials, and observational studies were included. The primary outcome was all-cause mortality. Odds ratios (OR) with 95% confidence intervals (CI) were pooled. Four AI tools were used: Consensus, Perplexity, Elicit, and Scite. SETTING Intensive care medicine. PATIENTS OR PARTICIPANTS One thousand six hundred and thirty-six studies were identified, with 10 studies included in the MTA. INTERVENTIONS No interventions. MAIN VARIABLES OF INTEREST Mortality, efficacy, and safety. RESULTS ATII shows a trend towards mortality reduction when compared with controls, OR 0.86 (95% CI: 0.60-1.23); this reduction reaches significance in patient subgroups: High Renin Levels, OR 0.45 (95% CI: 0.22-0.93); shock with renal replacement therapy, OR 0.38 (95% CI: 0.17-0.84). ATII is very effective in increasing mean arterial pressure, OR 3.25 (95% CI: 2.24-4.73), without increasing events, OR 0.77 (95% CI: 0.51-1.14). The AI reached the same conclusions, but only 25%-30% of the studies were included in the MTA. CONCLUSIONS ATII effectively increases blood pressure without side effects and without altering mortality. AI can assist in evaluating clinical evidence.

• Publication year

  2025

• Venue

  Medicina Intensiva

• Publication date

  2025-11-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1016/j.medine.2025.502269PMID 41219026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of generative artificial intelligence in medical research

  2024cited by this paper
• Can artificial intelligence help for scientific writing?

  2023cited by this paper
• ChatGPT and Artificial Intelligence in Hospital Level Research: Potential, Precautions, and Prospects

  2023cited by this paper
• Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

  2023cited by this paper
• A PILOT STUDY OF ANGIOTENSIN II AS PRIMARY VASOPRESSOR IN CRITICALLY ILL ADULTS WITH VASODILATORY HYPOTENSION: THE ARAMIS STUDY

  2023cited by this paper
• Evaluating the efficacy of artificial intelligence tools for the automation of systematic reviews in cancer research: A systematic review.

  2023cited by this paper
• ChatGPT in education: A blessing or a curse? A qualitative study exploring early adopters’ utilization and perceptions

  2023cited by this paper
• Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU

  2022cited by this paper
• Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021

  2021cited by this paper
• Tools to support the automation of systematic reviews: A scoping review.

  2021cited by this paper
• Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial

  2020cited by this paper
• Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study.

  2020cited by this paper
• Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

  2018cited by this paper
• Angiotensin II for the Treatment of Vasodilatory Shock

  2017cited by this paper
• Artificial intelligence in healthcare: past, present and future

  2017cited by this paper
• Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

  2014cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

  2004cited by this paper
• Angiotensin in cardiac surgery: efficacy in patients on angiotensin converting enzyme inhibitors

  2001cited by this paper
• Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion.

  1994cited by this paper
• Angiotensin‐Induced Hypertension Chemotherapy in Children with Advanced Solid Tumors

  1991cited by this paper
• The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy.

  1982cited by this paper
• Effect of Prolonged Low‐Dose Angiotensin II Infusion on the Sensitivity of Adrenal Cortex in Man

  1975cited by this paper
• PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES.

  1965cited by this paper
• Acute hemodynamic effects of angiotensin II. Preliminary report.

  1963cited by this paper
• THE HEMODYNAMIC EFFECTS OF ANGIOTONIN IN NORMAL MAN.

  1941cited by this paper

• No citing papers are available for this paper.